Senior leader brings deep biotech and pharmaceutical industry experience
Concarlo Therapeutics (“Concarlo”), a pre-clinical biotech company whose mission is to dramatically improve outcomes for patients with drug resistant cancers by creating transformative therapies that control the p27 target, has hired Vadim Shepel as Chief Business & Operating Officer. In this newly created role, Mr. Shepel will lead all aspects of Concarlo’s business strategy, including business development, finances, operations and investor relations. He joins Concarlo from BeiGene where he was the Senior Director of New Market Development. Previously he spent five years at Pfizer where he was the Director of Strategy and Consulting in the Vaccines and Hospital Business Units. Mr. Shepel reports to Dr. Stacy Blain, Concarlo’s Co-Founder and Chief Scientific Officer.
Building a high performing team that can translate scientific innovation into commercially viable therapeutics is key to saving more lives among those who are diagnosed with cancer. Advances in precision oncology have made the outlook for people with cancer more hopeful than ever. Through molecular profiling and genetic sequencing, medical professionals are now matching patients with the treatments that stand the highest likelihood of success. Yet, despite this great progress, more than 600,000 patients continue dying each year in the U.S. from cancer.
“Vadim is a highly talented executive who will help drive Concarlo’s business strategy and operations and he will play a critical role in the development of our business,” said Dr. Blain. “He joins our world-class leadership team which will enable us to achieve our vision to create a world of possibility, hope and time by making cancer a treatable, manageable and survivable condition.”
“I believe that addressing drug resistance is one of the most pressing issues in cancer care and the next paradigm shift in oncology. I am thrilled to join Concarlo’s team, work alongside renowned experts from across scientific disciplines, and bring the company’s transformative therapy to patients,” said Mr. Shepel.
Concarlo has assembled an experienced team of purpose-driven leaders in science and business, including:
- Dr. Stacy Blain, Co-Founder and Chief Scientific Officer
- Jason Mraz, President
- Dr. Krishna Allamneni, Chief Development Officer
- Sean Larkin, Head of Operations
The company has also created a Business Advisory Board comprised of a number of highly regarded leaders, including:
- Jay Campbell, Managing Director, Clinical Accelerator and Venture Fund at Cancer Research Institute (CRI)
- Dr. Alicia Chung, Strategy & Business Development at Bionaut Labs
- Michael Harrington, Former Senior Vice President and General Counsel at Eli Lilly and Company
- Arthur Klausner, President & CEO, Goldilocks Therapeutics
- Michael P. Miller, Former EVP Commercial, Jazz Pharmaceuticals
